tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Alphamab Oncology’s JSKN003 Receives Breakthrough Therapy Designation

Story Highlights
  • Alphamab Oncology specializes in bispecific antibodies and ADCs for cancer treatment.
  • JSKN003 received breakthrough therapy designation, expediting its development and approval.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Alphamab Oncology’s JSKN003 Receives Breakthrough Therapy Designation

Elevate Your Investing Strategy:

The latest update is out from Alphamab Oncology ( (HK:9966) ).

Alphamab Oncology announced that its drug JSKN003 has received breakthrough therapy designation from China’s National Medical Products Administration for treating certain types of cancer, including platinum-resistant recurrent epithelial ovarian cancer. This designation is expected to expedite the drug’s clinical development and approval process, potentially benefiting more patients sooner and enhancing Alphamab’s positioning in the oncology market.

More about Alphamab Oncology

Alphamab Oncology is a leading biopharmaceutical company in China, specializing in bispecific antibodies, multifunctional protein engineering, and antibody-drug conjugates (ADCs). The company has a robust in-house pipeline for oncology treatments, including monoclonal antibodies, bispecific antibodies, and ADCs, with one product approved for marketing and others in late clinical stages.

YTD Price Performance: 58.29%

Average Trading Volume: 4,729,304

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$5.35B

Find detailed analytics on 9966 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1